Edesa Biotech, Inc. (EDSA)
2025-06-30 | ||||
|---|---|---|---|---|
| Exchange differences on translation | 164,611 | |||
| Income tax expense | - | |||
| Research and development | 939,067 | |||
| General and administrative | 964,676 | |||
| Loss from operations | -1,903,743 | |||
| Misc other income | - | |||
| Interest income | 572 | |||
| Reimbursement grant income | 183,281 | |||
| Foreign exchange loss | -29,574 | |||
| Nonoperating income (expense) | 154,279 | |||
| Loss before income taxes | -1,749,464 | |||
| Net loss | -1,749,464 | |||
| Net comprehensive loss | -1,584,853 | |||
| Loss per common share - basic and diluted (in dollars per share) | -0.25 | |||
| Weighted average number of common shares (in shares) | 7,022,678 | |||